Chemo Spain – Leandro Sigman, General Manager
Leandro Sigman, general manager of Chemo, discusses changes in the Spanish market and the company’s strategy to target international markets. The crisis has changed the way companies operate in…
Established over 35 years ago, Chemo operates across the entire pharmaceutical value chain, delivering specialized expertise and experience in scientific research, development, manufacturing, sales and marketing of a wide range of active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and branded pharmaceuticals, both for human and animal health.
While the main offices are located in Madrid, Lugano and Buenos Aires, Chemo is acting worldwide, creating a broad and balanced manufacturing and commercial network across major pharmaceutical markets in Europe, America, Asia and Africa, to address global opportunities and customers` needs.
Chemo`s activity is organized in three synergistic business areas: industrial, branded and biotech, with over 5,000 professionals in more than 40 countries, across four continents, ten state-of-the-art manufacturing facilities, nine specialized R&D centers, 12 commercial offices and 33 pharmaceutical affiliates, serving 1,150 customers in 96 countries around the world.
Chemo believes in innovation and sustainable development. The company’s commitment is to improve people`s health and quality of life, providing access to safe, quality and affordable medicines, and to continuously expand its efforts and R&D investment to develop new and better therapies.
Contact details:
Chemo Barcelona
Gran Vía Carlos III, 98 7th floor
08028 Barcelona , Spain.
Tel: + 34 93 330 62 12
Fax: + 34 93 330 27 62
BarcelonaChemo@chemogroup.com
Leandro Sigman, general manager of Chemo, discusses changes in the Spanish market and the company’s strategy to target international markets. The crisis has changed the way companies operate in…
CataloniaBio & HealthTech is an industry association representing the biomedicine and health sector in Catalonia. Its CEO, Judit Anido, explains how the region’s entrepreneurial spirit is helping it lead Spain…
Sobi’s VP and general manager for Spain and Portugal, Pablo De Mora, comments on his experience during the pandemic, the Swedish company’s haematology and immunology portfolio, including its EMA-approved COVID-19…
Lilly’s Nabil Daoud highlights the evolution in the firm’s Spanish manufacturing and R&D footprint in recent years, discussed launch plans for its next-generation diabetes and obesity treatments, and outlines some…
STADA’s general manager for Spain, Mar Fabregas, reveals how the acquisition of parts of GSK and Sanofi’s portfolio is helping the global generics company better compete in consumer health. In…
The Spanish Society of Biotechnology (SEBiot) is a non-profit organization established by academics and researchers to promote the sector through knowledge exchange and is a Branch Office of the European…
As Spain’s Prime Minister, Pedro Sanchez, became the latest leader to call for COVID-19 to be treated as an endemic illness like the flu, regional health authorities warn that it…
While Spain’s scientific infrastructure has long been hailed as world-class, the southern European nation has often struggled to translate its excellent science into viable commercial companies. However, a growing cadre…
The executive president of Laboratorios Rubió, Carlos Rubió, analyses the fundamentals behind the Catalan company’s double-digit growth, its international expansion plan, which includes the United States, the doubling of capacity…
The Spanish Association of Orphan and Ultra Orphan Medicinal Products Laboratories (AELMHU) is a non-profit organisation working to improve awareness about rare diseases and access of Orphan Drugs. Maria Jose…
Maria Jose Sanchez Losada, general manager for CSL Behring Iberia, highlights the challenges that plasma-derived therapies faced during the COVID-19 pandemic, how the firm competes with well-established local players in…
mAbxience’s CEO Emmanuelle Lepine highlights the company’s international expansion into highly regulated markets, new investment into its Spanish manufacturing facility, and its partnership with AstraZeneca on COVID-19 vaccine manufacturing in…
According to recent IQVIA and industry association reports, the Spanish pharma market, valued at EUR 21.6 billion per year, continues to grow at a relatively slow pace. Other key trends…
See our Cookie Privacy Policy Here